Biocon Pharma collaborates with DKSH

Biocon Ltd today announced that Biocon’s subsidiary, Biocon Pharma Limited and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma’s generic formulations in Singapore and Thailand.

Under the terms of the agreement, DKSH will gain an exclusive license to register and commercialise these seven generic formulations from various therapeutic areas like diabetology, cardiology, oncology and immunology, which will be sold under Biocon’s brand in Singapore and Thailand.

DKSH will manage marketing and sales as well as logistics for Biocon Pharma, helping drive sales growth through its capabilities and strengths in the medical and pharmacy channels. DKSH helps company to grow its business in new and existing markets. It is a leading market expansion services provider with a special focus on Asia. 

DKSH Holding AG is Switzerland-based company and is listed on SIX Swiss Exchange. The company’s business activities include four business units: Consumer Goods, Healthcare, Performance Materials and Technology. It has significant presence in Thailand. In FY19, 33.9 per cent of its net sales came from Thailand.

This development is in-line with Biocon’s strategy for expansion of its generic formulations business through licensing of its drug products in multiple markets.

Thailand and Singapore are the two large markets in South East Asia region. Additionally, Krungsri Research’s forecast is that in the period during 2019-2021, the value of pharmaceuticals distributed to Thai domestic market is expected to grow by 4.2-4.6 per cent. India is one of the top five pharma exporters in Thailand.

Biocon stock opened at 382, up  Rs 0.50 per share from its previous day's close.